Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPASIL-ESIDRIX #2 vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Serpasil-Esidrix #2 contains reserpine and hydrochlorothiazide. Reserpine irreversibly inhibits the vesicular monoamine transporter 2 (VMAT2) in the CNS and peripheral sympathetic nerve endings, depleting norepinephrine, dopamine, and serotonin from storage vesicles, leading to reduced sympathetic outflow and antihypertensive effect. Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal renal tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume and peripheral vascular resistance.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
1 tablet orally once daily. Each tablet contains 0.25 mg reserpine and 50 mg hydrochlorothiazide.
250 mg orally twice daily
Reserpine: 50-100 hours (biphasic; terminal phase 11-16 days due to slow release from adrenergic storage sites); Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment).
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Reserpine is extensively metabolized in the liver via hydrolysis and conjugation, with metabolites excreted in urine and feces. Hydrochlorothiazide is not metabolized extensively; it is primarily eliminated unchanged by the kidneys.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Reserpine: 60% renal (as metabolites), 40% fecal (as parent drug and metabolites); Hydrochlorothiazide: >95% renal (unchanged) via tubular secretion.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Reserpine: 96% bound to albumin; Hydrochlorothiazide: 40-68% bound to albumin.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Reserpine: 5-8 L/kg (extensive tissue binding, particularly to adrenergic neurons); Hydrochlorothiazide: 0.83-1.14 L/kg (distributes into extracellular fluid).
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Reserpine: 50-60% (oral, extensive first-pass metabolism); Hydrochlorothiazide: 65-75% (oral, with food decreasing absorption by 10-20%).
70-90% (oral); 100% (IV).
Contraindicated if GFR < 30 m L/min. For GFR 30-59 m L/min, maximum dose is 1 tablet every other day due to hydrochlorothiazide accumulation.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: caution, consider reducing dose. Child-Pugh B: contraindicated due to risk of hepatic coma and reserpine-induced depression. Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not recommended for children. Safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Initiate with 0.5 tablet once daily due to increased sensitivity to reserpine (CNS depression) and hydrochlorothiazide (hypotension, electrolyte imbalance). Titrate slowly.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Reserpine may cause depression, and should be discontinued if symptoms occur; use with caution in patients with history of depression.,Hydrochlorothiazide may cause electrolyte imbalances (e.g., hypokalemia), dehydration, and increased serum uric acid and glucose.,May cause orthostatic hypotension, especially with alcohol or other antihypertensives.,Renal impairment: monitor renal function.,Hepatic impairment: use with caution as reserpine may precipitate hepatic encephalopathy.,Sulfonamide allergy: hydrochlorothiazide is a sulfonamide derivative; cross-sensitivity may occur.,May require dosage adjustment in renal impairment.,Avoid abrupt discontinuation of reserpine; taper gradually.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to reserpine, hydrochlorothiazide, or sulfonamides.,History of mental depression or suicidal tendencies.,Active peptic ulcer or ulcerative colitis.,Electroconvulsive therapy (ECT) within 7 days.,Anuria or severe renal impairment (e.g., creatinine clearance <30 m L/min).,Pheochromocytoma (reserpine may paradoxically increase blood pressure).
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
High-potassium foods (bananas, oranges, spinach) may increase risk of hyperkalemia if used with potassium-sparing diuretics; however, hydrochlorothiazide is potassium-wasting, so hypokalemia risk exists. Avoid excessive sodium intake (processed foods, salt) as it can reduce antihypertensive effect. Grapefruit juice may interact with reserpine; limit consumption.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
Serpasil (reserpine) is classified as FDA Pregnancy Category C. Reserpine crosses the placenta. First trimester: Limited human data, but animal studies suggest increased risk of skeletal and cardiovascular anomalies. Second and third trimesters: Possible adverse effects including neonatal respiratory depression, bradycardia, hypothermia, and hypotonia. Esidrix (hydrochlorothiazide) is FDA Pregnancy Category B; however, thiazide diuretics may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Use only if clearly needed.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Reserpine is excreted into breast milk; M/P ratio not established. Potential for severe adverse effects in nursing infants including respiratory depression, bradycardia, and hypotonia. Hydrochlorothiazide is excreted in breast milk in low amounts (M/P ratio approximately 0.4-0.5), but may suppress lactation and cause electrolyte disturbances. Avoid breastfeeding during therapy.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
Pregnancy can increase volume of distribution and renal clearance, potentially reducing drug concentrations. No specific dose adjustment studies for Serpasil-Esidrix #2; however, based on components: Hydrochlorothiazide may require increased dose due to enhanced clearance, but use lowest effective dose. Reserpine dosing should be minimized due to fetal risks. Avoid use in pregnancy if possible; alternative antihypertensives recommended.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Serpasil (reserpine) plus Esidrix (hydrochlorothiazide) #2 is a fixed-dose combination for hypertension. Reserpine depletes catecholamines: monitor for depression, nasal congestion, sedation, and bradycardia. Hydrochlorothiazide: check electrolytes, uric acid, glucose; avoid in anuria. Onset of reserpine action is slow (weeks) but prolonged (weeks after discontinuation). Combination may exacerbate gout and diabetes.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take exactly as prescribed; do not stop suddenly as high blood pressure may worsen.,May cause drowsiness or dizziness; avoid driving or operating heavy machinery until effects are known.,Avoid alcohol as it can increase dizziness and drowsiness.,Report symptoms of depression, slow heart rate, severe nasal congestion, or unusual bleeding/bruising.,Use sun protection as hydrochlorothiazide increases sun sensitivity.,Monitor for signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, excessive thirst.,Inform all healthcare providers you are taking this medication, especially before surgery.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPASIL-ESIDRIX #2 vs ALDOCLOR-250, answered by our medical review team.
SERPASIL-ESIDRIX #2 is a Antihypertensive Combination that works by Serpasil-Esidrix #2 contains reserpine and hydrochlorothiazide. Reserpine irreversibly inhibits the vesicular monoamine transporter 2 (VMAT2) in the CNS and peripheral sympathetic nerve endings, depleting norepinephrine, dopamine, and serotonin from storage vesicles, leading to reduced sympathetic outflow and antihypertensive effect. Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal renal tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume and peripheral vascular resistance.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPASIL-ESIDRIX #2 and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPASIL-ESIDRIX #2 is: 1 tablet orally once daily. Each tablet contains 0.25 mg reserpine and 50 mg hydrochlorothiazide.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPASIL-ESIDRIX #2 and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPASIL-ESIDRIX #2 is classified as Category C. Serpasil (reserpine) is classified as FDA Pregnancy Category C. Reserpine crosses the placenta. First trimester: Limited human data, but animal studies suggest increased risk of sk. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.